Cargando…

Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade

PAK4 inhibition can sensitize tumors to immune checkpoint blockade (ICB) therapy; however, the underlying mechanisms remain unclear. We report that PAK4 inhibition reverses immune cell exclusion by increasing the infiltration of CD8 T cells and CD103(+) dendritic cells (DC), a specific type of DCs t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abril-Rodriguez, Gabriel, Torrejon, Davis Y., Karin, Daniel, Campbell, Katie M., Medina, Egmidio, Saco, Justin D., Galvez, Mildred, Champhekar, Ameya S., Perez-Garcilazo, Ivan, Baselga-Carretero, Ignacio, Singh, Jas, Comin-Anduix, Begoña, Puig-Saus, Cristina, Ribas, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799984/ https://www.ncbi.nlm.nih.gov/pubmed/36588582 http://dx.doi.org/10.1158/2767-9764.CRC-21-0133

Ejemplares similares

Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade
por: Frankiw, Luke, et al.
Publicado: (2023)

ERK mediates interferon gamma-induced melanoma cell death
por: Champhekar, Ameya, et al.
Publicado: (2023)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
por: Garcia-Diaz, Angel, et al.
Publicado: (2017)

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009)

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
por: Comin-Anduix, Begoña, et al.
Publicado: (2010)

Gene editing: Towards the third generation of adoptive T-cell transfer therapies
por: Puig-Saus, Cristina, et al.
Publicado: (2019)

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
por: Robert, Lidia, et al.
Publicado: (2014)

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
por: Parisi, Giulia, et al.
Publicado: (2020)

A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication
por: Zhou, Jing, et al.
Publicado: (2018)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

Tremelimumab: research and clinical development
por: Comin-Anduix, Begoña, et al.
Publicado: (2016)

A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer
por: Nguyen, Vina P., et al.
Publicado: (2023)

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure
por: Shin, Daniel, et al.
Publicado: (2015)

Functional Deficits in Pak5, Pak6 and Pak5/Pak6 Knockout Mice
por: Furnari, Melody A., et al.
Publicado: (2013)

Beyond the immediate tumor microenvironment: distinct T cell phenotype and function of tumor-adjacent healthy breast tissue associated with regional metastasis in breast cancer
por: Guo, Yi, et al.
Publicado: (2014)

The Retinoblastoma Tumor Suppressor Transcriptionally Represses Pak1 in Osteoblasts
por: Sosa-García, Bernadette, et al.
Publicado: (2015)

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody
por: Escuin-Ordinas, Helena, et al.
Publicado: (2013)

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products
por: Nowicki, Theodore S., et al.
Publicado: (2018)

HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
por: Curtin, James F, et al.
Publicado: (2009)

PAK1, PAK1Δ15, and PAK2: similarities, differences and mutual interactions
por: Grebeňová, Dana, et al.
Publicado: (2019)

Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy
por: Campbell, Katie M, et al.
Publicado: (2022)

Differential roles and regulation of the protein kinases PAK4, PAK5 and PAK6 in melanoma cells
por: Murugesan, Gavuthami, et al.
Publicado: (2022)

Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab
por: Ibarrondo, F. Javier, et al.
Publicado: (2013)

Crystal Structures of the p21-Activated Kinases PAK4, PAK5, and PAK6 Reveal Catalytic Domain Plasticity of Active Group II PAKs
por: Eswaran, Jeyanthy, et al.
Publicado: (2007)

Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
por: Escuin-Ordinas, Helena, et al.
Publicado: (2021)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Regulation of early T-lineage gene expression and developmental progression by the progenitor cell transcription factor PU.1
por: Champhekar, Ameya, et al.
Publicado: (2015)

PAK Signaling in Oncogenesis
por: Molli, Poonam R., et al.
Publicado: (2009)

PAK signaling in cancer
por: Ye, Diana Zi, et al.
Publicado: (2012)

Expansion of BCR/ABL1 (+) cells requires PAK2 but not PAK1
por: Edlinger, Leo, et al.
Publicado: (2017)

PAK4 signaling in health and disease: defining the PAK4–CREB axis
por: Won, So-Yoon, et al.
Publicado: (2019)

PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary
por: Parks, Sydney E., et al.
Publicado: (2021)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis
por: Palaskas, Nicolaos Jay, et al.
Publicado: (2019)

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
por: Niehr, Franziska, et al.
Publicado: (2011)

Direct Interaction between AR and PAK6 in Androgen-Stimulated PAK6 Activation
por: Liu, Xia, et al.
Publicado: (2013)

LIGHTing tumor up for checkpoint blockade
por: Liang, Yong, et al.
Publicado: (2016)

PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
por: Mpilla, Gabriel, et al.
Publicado: (2019)

The Combined Use of Orf Virus and PAK4 Inhibitor Exerts Anti-tumor Effect in Breast Cancer
por: Deng, Hao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iqshh9rgkpnfeuc7prn8pqrnh3